Pediatric Orphan Indications
Ganaxolone is currently being evaluated in an ongoing Phase 2 open-label exploratory study as a treatment for orphan, genetic epilepsies (PCDH19, CDKL5 & Lennox Gastaut Syndrome). Currently, there are no FDA approved therapies for these conditions. More information about the trial can be found on www.clinicaltrials.gov, using Identifier NCT02358538.
PCDH19 Pediatric Epilepsy
PCDH19 pediatric epilepsy is a serious and rare epileptic syndrome characterized by highly variable early-onset cluster seizures with comorbid cognitive and behavioral disturbances with or without intellectual disability. PCDH19 pediatric epilepsy is caused by a mutation in the PCDH19 gene. There is indirect evidence linking progesterone and allopregnanolone to the onset and offset of seizures in girls with PCDH19 pediatric epilepsy.
Clinical Development of Ganaxolone in PCDH19 Pediatric Epilepsy
We have completed the PCDH19 cohort in the study which enrolled 11 females. In this severe patient population, ganaxolone reduced seizure frequency from baseline in the majority of patients and was generally safe and well tolerated.
CDKL5 is a serious and rare genetic disorder that is caused by a mutation of the cyclin-dependent kinase-like 5 (CDKL5) gene, located on the X chromosome. It predominantly affects girls and is characterized by early-onset, difficult-to-control seizures and severe neuro‑developmental impairment. The CDKL5 gene encodes proteins essential for normal brain function. Most children affected by CDKL5 cannot walk, talk, or care for themselves. Many also suffer from scoliosis, visual impairment, gastrointestinal difficulties, and sleeping disorders. Currently, there are no approved therapies for CDKL5 disorder. No previous formal clinical trials have been conducted in this population.
Clinical Development of Ganaxolone in CDKL5 Disorder
We recently reported top-line data from the Phase 2 open-label study in patients with CDKL5 disorder. Oral ganaxolone, in addition to baseline treatment, showed a sizable and durable seizure-frequency reduction in the majority of patients, with some achieving an increase in the number of seizure-free days and reporting behavioral benefits. Ganaxolone was generally safe and well-tolerated with no serious adverse events. Based upon these robust CDKL5 disorder clinical results and etiologic fit with ganaxolone’s mechanism of action, we have prioritized CDKL5 disorder as our lead pediatric orphan program for advancement into later stage clinical development. We plan to meet with regulatory agencies to obtain agreement on the clinical development plan that would be needed for approval of ganaxolone for CDKL5 disorder.
Fragile X Syndrome
Photo Credit: Peter Saxon (CC BY-SA)
Fragile X Syndrome (FXS) is a genetic condition, caused by a mutation in the fmr1 gene, and is characterized by the development of a range of developmental problems, including cognitive impairment, learning disabilities and behavioral challenges. Ganaxolone and other agents that have been shown to improve GABA function have also been shown to improve FXS symptoms in a mouse model. Ganaxolone may increase signaling at existing receptors to normalize GABA function, thereby reducing anxiety, hyperactivity and other disabilities associated with this inherited disorder.
Clinical Development of Ganaxolone in FXS
Ganaxolone was evaluated for the treatment of anxiety and attention in children with FXS in a Phase 2 exploratory clinical trial. Consistent with our expectations and ganaxolone’s mechanism of action, treatment with ganaxolone improved anxiety and hyperactivity across multiple measures in FXS patients with high baseline anxiety. In addition ganaxolone was generally safe and well tolerated. The results from this study support the anxiolytic effect of ganaxolone and provide a strong rationale to advance the clinical development of ganaxolone in anxious FXS patients.